Breaking News Instant updates and real-time market news.

FINL

Finish Line

$11.32

0.2 (1.80%)

, TBT

ProShares UltraShort 20+ yr Trsry

$35.88

0.26 (0.73%)

08:45
10/06/17
10/06
08:45
10/06/17
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Finish Line (FINL) 1.37% +0.50, ProShares UltraShort Lehman 20 plus Year Treasury (TBT) 2.26% +0.38, Intercept (ICPT) 6.12% +0.15, Chesapeake (CHK) 2.85% +0.10, SeaWorld (SEAS) 3.04% +0.06, Eros International (EROS) 51.01% +0.02, and CenturyLink (CTL) 0.69% +0.01.

FINL

Finish Line

$11.32

0.2 (1.80%)

TBT

ProShares UltraShort 20+ yr Trsry

$35.88

0.26 (0.73%)

ICPT

Intercept

$72.76

4.03 (5.86%)

CHK

Chesapeake

$4.30

0.03 (0.70%)

SEAS

SeaWorld

$13.19

-0.92 (-6.52%)

EROS

Eros International

$15.25

1.1 (7.77%)

CTL

CenturyLink

$20.02

-0.07 (-0.35%)

  • 06

    Oct

  • 06

    Nov

FINL Finish Line
$11.32

0.2 (1.80%)

10/02/17
SUSQ
10/02/17
DOWNGRADE
SUSQ
Neutral
Finish Line downgraded to Neutral from Positive at Susquehanna
10/02/17
SUSQ
10/02/17
DOWNGRADE
Target $12
SUSQ
Neutral
Finish Line downgraded to Neutral at Susquehanna
As previously reported, Susquehanna Sam Poser downgraded Finish Line to Neutral from Positive following its recent advance which pushed the stock past his price target. He continues to believe there is a high probability the company will be acquired by Sports Direct. Poser sees a $13.30 takeout price on Finish Line and sees downside risk for the stock to $8 if a takeout fails to occur. Poser has a $12 price target on Finish Line shares.
09/29/17
WELS
09/29/17
NO CHANGE
Target $12
WELS
Market Perform
Finish Line takeout could be in $14-$16 per share range, says Wells Fargo
Wells Fargo analyst Tom Nikic pegs Finish Line's takeout range at $14-$16 per share after the New York Post reported that the company is in talks to sell itself to U.K.- based retailer Sports Direct. Finish Line closed yesterday up 41c, or 4%, to $11.66. A potential deal could result in "significant upside" to Finish Line shares, Nikic tells investors in a research note. He believes a deal could make sense from Sports Direct's perspective and raised his price target for Finish Line shares to $12 from $9. The new price target assumes a 50% probability that a deal occurs. Nikic keeps a Market Perform rating on Finish Line.
09/25/17
SUSQ
09/25/17
NO CHANGE
Target $12
SUSQ
Positive
Finish Line takeout thesis remains intact, says Susquehanna
Susquehanna analyst Sam Poser is telling investors to buy Finish Line shares as little has changed with his thesis following its Q2 results. The analyst noted fundamentals remain weak but he continues to believe Sports Direct will acquire the company and puts the odds at 75%. Poser has a $12 price target on Finish Line shares.
TBT ProShares UltraShort 20+ yr Trsry
$35.88

0.26 (0.73%)

ICPT Intercept
$72.76

4.03 (5.86%)

10/06/17
GHSC
10/06/17
INITIATION
Target $136
GHSC
Buy
Intercept initiated with a Buy at Seaport Global
Seaport Global analyst Vernon Bernardino initiated Intercept with a Buy and $136 price target. The analyst expects Q4 prescription trends will support growing confidence that the FDA's statement has not had a longterm effect on Ocaliva Rx behavior in its approved use in patients with primary biliary cholangitis.
10/04/17
10/04/17
DOWNGRADE

Market Perform
Intercept downgraded on reduced NASH expectations at JMP Securities
As previously reported, JMP Securities analyst Liisa Bayko downgraded Intercept to Market Perform from Outperform after she adjusted her assumptions for market penetration of Ocaliva in NASH given the rapidly evolving competitive landscape and cases of serious liver injury and deaths reported in Ocaliva-treated PBC patients. The analyst, who has removed cirrhotic patients from her NASH model to be conservative, now believes Intercept is fairly valued at current levels.
10/04/17
JMPS
10/04/17
DOWNGRADE
JMPS
Market Perform
Intercept downgraded to Market Perform from Outperform at JMP Securities
10/02/17
RBCM
10/02/17
NO CHANGE
RBCM
Enanta data positive, says RBC Capital
RBC Capital analyst Brian Abrahams says that preclinical data on Enanta's (ENTA) EDP-305 presented at the AASLD conference "shows comparable-to-better effects on fibrosis to other anti-fibrotic agents." The analyst says that although the test was done on rats, other anti-fibrotic agents' impact on fibrosis in rats has been similar to their impact on fibrosis in humans. The analyst adds that the data indicates that EDP-305 may have a more beneficial effect on cholesterol genes than Intercept's (ICPT) Ocaliva drug. The analyst predicts that Phase I data on Enanta's drug, expected to be presented at the end of the conference, to be positive and potentially cause the shares to rise. He keeps an Outperform rating on Enata.
CHK Chesapeake
$4.30

0.03 (0.70%)

09/05/17
TUDR
09/05/17
DOWNGRADE
TUDR
Hold
Chesapeake downgraded to Hold from Buy at Tudor Pickering
09/19/17
IMPC
09/19/17
INITIATION
Target $5
IMPC
In-Line
Chesapeake initiated with an In-Line at Imperial Capital
Imperial Capital analyst Jason Wangler started Chesapeake Energy with an In-Line rating and $5 price target.
06/21/17
MACQ
06/21/17
DOWNGRADE
MACQ
Underperform
Chesapeake downgraded to Underperform from Neutral at Macquarie
Macquarie analyst Paul Grigel downgraded Chesapeake with a $3.50 price target citing increasing liquidity concerns against limited core inventory. The analyst does not expect a material portfolio improvement that will offset longer-term challenges.
06/15/17
WOLF
06/15/17
INITIATION
Target $5.5
WOLF
Peer Perform
Chesapeake initiated with a Peer Perform at Wolfe Research
Wolfe Research initiated Chesapeake with a Peer Perform and a $5.50 price target.
SEAS SeaWorld
$13.19

-0.92 (-6.52%)

10/05/17
RHCO
10/05/17
NO CHANGE
RHCO
SeaWorld combination with Merlin 'could make sense,' says SunTrust
After Bloomberg reported that Merlin Entertainments had spoken with SeaWorld about a potential sale of its park assets, SunTrust analyst Michael A. Swartz says that such a deal "could make sense." The analyst says that the deal could be logical because both companies have assets in Southern California and Florida and have a customer base dominated by families with young children. He adds that Merlin has "a stronger balance sheet" and "a track record" of making acquisitions in the space, and he believes that a deal could enable the companies to compete more effectively against the larger players in their markets. But he believes the two investors who own roughly a combined 35% of SeaWorld's outstanding shares could prevent a transaction. The analyst keeps a $16 price target and a Buy rating on SeaWorld.
08/09/17
STFL
08/09/17
NO CHANGE
STFL
'Many' SeaWorld initiatives seem to be ' working,' says Stifel
Stifel analyst Steven Wieczynski says that calling SeaWorld's Q2 results disappointing "would be an understatement." However, the analyst says that "many of the company's "strategic initiatives" appear to be "working," and he says the stock remains attractive at current levels. The analyst cut his price target to $16 from $23 but keeps a Buy rating on the shares.
09/15/17
SBSH
09/15/17
NO CHANGE
Target $14
SBSH
Neutral
Citi now sees Busch Gardens sale as more likely for SeaWorld
Citi analyst Jason Bazinet raised his probability of a Busch Gardens asset sale for SeaWorld Entertainment to 65% from 30%. He sees $2 of upside for the shares in the event of a sale. The company's lower EBITDA forecast suggests debt covenants may move to the forefront, Bazinet tells investors in a research note. He adds that press reports suggest Merlin Entertainment is interested in the parks. The analyst, however, reduced his price target for SeaWorld shares to $14 from $15. This reflects his new $12 per share standalone valuation for the company as well as $2 for a potential Busch Gardens sale. Bazinet keeps a Neutral rating on SeaWorld.
08/30/17
KEYB
08/30/17
INITIATION
KEYB
Sector Weight
SeaWorld resumed with a Sector Weight from Overweight at KeyBanc
KeyBanc analyst Brett Andress resumed coverage of SeaWorld with a Sector weight rating. The firm previously had an Overweight rating on the name.
EROS Eros International
$15.25

1.1 (7.77%)

12/09/16
WELS
12/09/16
UPGRADE
WELS
Outperform
Eros International upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Eric Katz upgraded Eros International to Outperform citing more confidence in the name after news yesterday that ErosNow hit 2M paid subscribers two quarters ahead of schedule. The company's new business-to-business model is working, Katz tells investors in a research note. He raised his price target range for the shares to $18-$20 from $16-$18.
08/07/17
WELS
08/07/17
NO CHANGE
WELS
Outperform
Eros library sale and reverse merger both make sense, says Wells Fargo
Wells Fargo analyst Eric Katz noted that media reports indicate Eros (EROS) is said to be in talks to possibly sell its library of film rights, and possibly its over-the-top streaming service, to Apple (AAPL), Amazon (AMZN) or Netflix (NFLX). A media report also claims the company could be looking to "reverse merge" its NYSE-listed entity into is Indian-listed subsidiary. Both moves would make sense, said Katz, who keeps an Outperform rating on Eros share, which are up 23% to $10.10 in early trading.
CTL CenturyLink
$20.02

-0.07 (-0.35%)

10/04/17
LEHM
10/04/17
NO CHANGE
Target $19
LEHM
Underweight
Barclays lowers price targets for CenturyLink, Level 3
Barclays analyst Amir Rozwadowski lowered his price target for Underweight-rated CenturyLink (CTL) to $19 from $23 and for Equal Weight-rated Level 3 Communications (LVLT) to $53 from $59. The combination of downward estimate revisions, management changes and a delay in the timing of merger close has heightened the perceived challenges facing the joint entity, Rozwadowski tells investors in a research note. The analyst, however, sees less downside potential for CenturyLink based on his new price target. He believes improved clarity on the joint entity's strategic priorities as well as the size and scope of synergy upside would "serve as a net benefit for helping the company recapture the narrative and provide a necessary realignment of investor expectations."
08/18/17
BOFA
08/18/17
NO CHANGE
Target $42
BOFA
Buy
CenturyLink and Level 3 deal moving forward, says BofA/Merrill
BofA/Merrill analyst David Barden said weakness in CenturyLink (CTL) appears related to reports that the regulatory timeline for the Level 3 (LVLT) merger could slip past the September 30 target date. Barden said Department of Justice timing remains on track but The California Public Utility Commission has a 60 day window to approve the deal. After 60 days, there is a potential lag of 30 days which would put the final approval timing in the first week of November, at the latest. Barden said a 5 week slippage is possible, but no delay is certain, and the regulatory time frame has zero bearing on the deal approval. Further, the analyst said some investors view Windstream's (WIN) surprise dividend cut as an indicator that CenturyLink may do the same post the Level 3 deal. Barden does not expect a cut and notes the company is not in the same position as Winstream and management stated it continues to pay its $2.16/share annual dividend and that the Level 3 acquisition improves the payout ratio. The analyst rates CenturyLink a Buy with a $42 price target.
08/23/17
MSCO
08/23/17
NO CHANGE
Target $26
MSCO
Overweight
CenturyLink, Uniti Group risk/reward attractive, says Morgan Stanley
Morgan Stanley analyst Simon Flannery is surprised by the magnitude of share declines for Overweight rated CenturyLink (CTL) and Uniti Group (UNIT) and continues to view risk/reward as attractive. Flannery said Q2 results showed cable continued to to drive consumer sub growth, reinforcing his view to own these two infrastructure assets that will benefit from growing business IP/mobile traffic. The analyst trimmed CenturyLink's price target to $26 from $27 and cut Uniti's to $24 from $32.
09/28/17
RAJA
09/28/17
NO CHANGE
RAJA
DOJ appointment catalyst for CenturyLink, Level 3 deal, says Raymond James
Makan Delrahim was finally confirmed by the Senate yesterday as head of the Department of Justice Antitrust Division, Raymond James analyst Frank Louthan tells investors in a research note. He believes not having an antitrust head is at least partially to blame for the delay in mergers and acquisitions in the Technology & Communications space this year, including outstanding transactions like CenturyLink (CTL)/Level 3 Communications (LVLT) and AT&T (T)/Time Warner (TWX), as well as potential deals like Sprint (S)/T-Mobile U.S. (TMUS). The appointment of Delrahim is a catalyst for the approval of CenturyLink's acquisition of Level 3, where the Department of Justice has been the bottleneck, Louthan writes.

TODAY'S FREE FLY STORIES

19:15
10/20/17
10/20
19:15
10/20/17
19:15
General news
Breaking General news story  »

Federal Reserve Chair…

ATRS

Antares Pharma

$2.18

0.06 (2.83%)

18:59
10/20/17
10/20
18:59
10/20/17
18:59
Hot Stocks
FDA cannot approve Antares Pharma's Xyosted NDA »

Antares Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

18:55
10/20/17
10/20
18:55
10/20/17
18:55
Conference/Events
Federal Reserve Chairperson delivers a lecture at NEC Dinner »

Federal Reserve…

SHIP

Seanergy Marine

$1.24

0.0199 (1.63%)

17:50
10/20/17
10/20
17:50
10/20/17
17:50
Syndicate
Breaking Syndicate news story on Seanergy Marine »

Seanergy Marine files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLI

Houlihan Lokey

$41.56

0.18 (0.43%)

17:49
10/20/17
10/20
17:49
10/20/17
17:49
Syndicate
Breaking Syndicate news story on Houlihan Lokey »

Houlihan Lokey files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

GEO

Geo Group

$26.20

0.2 (0.77%)

17:48
10/20/17
10/20
17:48
10/20/17
17:48
Syndicate
Breaking Syndicate news story on Geo Group »

Geo Group files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

, AIMT

Aimmune

$25.66

-0.06 (-0.23%)

17:37
10/20/17
10/20
17:37
10/20/17
17:37
Hot Stocks
DBV sinks following peanut allergy trial miss, Aimmune soars »

Shares of DBV…

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

KALV

KalVista

$11.26

1.99 (21.47%)

, DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:24
10/20/17
10/20
17:24
10/20/17
17:24
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: KalVista (KALV),…

KALV

KalVista

$11.26

1.99 (21.47%)

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPCI

Intellipharmaceutics

17:23
10/20/17
10/20
17:23
10/20/17
17:23
Hot Stocks
Breaking Hot Stocks news story on Intellipharmaceutics »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:21
10/20/17
10/20
17:21
10/20/17
17:21
Hot Stocks
DBV Technologies: PEPITES trial does not reach primary endpoint »

DBV Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$54.92

1.17 (2.18%)

17:08
10/20/17
10/20
17:08
10/20/17
17:08
Periodicals
Regulator criticizes Wells Fargo over deceptive auto insurance program, NYT says »

The Office of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 02

    Nov

  • 07

    Nov

  • 29

    Nov

  • 15

    Jan

ALIM

Alimera Sciences

17:01
10/20/17
10/20
17:01
10/20/17
17:01
Syndicate
Alimera Sciences to sell $25M in shares in an 'at the market offering' »

On October 20, Alimera…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYMC

Symantec

$32.66

0.33 (1.02%)

16:51
10/20/17
10/20
16:51
10/20/17
16:51
Syndicate
Breaking Syndicate news story on Symantec »

Symantec files to sell 1M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

EBMT

Eagle Bancorp

$19.55

0.15 (0.77%)

16:44
10/20/17
10/20
16:44
10/20/17
16:44
Hot Stocks
Breaking Hot Stocks news story on Eagle Bancorp »

EJF Capital reports 7%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KALV

KalVista

$11.26

1.99 (21.47%)

16:43
10/20/17
10/20
16:43
10/20/17
16:43
Hot Stocks
Breaking Hot Stocks news story on KalVista »

Longwood Fund II reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAGX

Jaguar Health

$0.19

0.002 (1.08%)

16:41
10/20/17
10/20
16:41
10/20/17
16:41
Syndicate
Breaking Syndicate news story on Jaguar Health »

Jaguar Health files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$345.10

-6.71 (-1.91%)

16:40
10/20/17
10/20
16:40
10/20/17
16:40
Hot Stocks
Tesla amends 'warehouse agreements' to increase commitments to $1.1B »

On October 18,Tesla…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 06

    Nov

SNV

Synovus

$47.30

0.54 (1.15%)

16:38
10/20/17
10/20
16:38
10/20/17
16:38
Hot Stocks
Synovus CBO sells 10,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

  • 15

    Nov

GTXI

GTx

$7.92

0.1 (1.28%)

16:38
10/20/17
10/20
16:38
10/20/17
16:38
Syndicate
Breaking Syndicate news story on GTx »

GTx files to sell 8.77M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASB

Associated Banc-Corp

$25.90

1.3 (5.28%)

, BKMU

BankMutual

$10.80

0.55 (5.37%)

16:36
10/20/17
10/20
16:36
10/20/17
16:36
Conference/Events
BankMutual to host special shareholder meeting »

Special Shareholder…

ASB

Associated Banc-Corp

$25.90

1.3 (5.28%)

BKMU

BankMutual

$10.80

0.55 (5.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

CNXR

Connecture

$0.49

-0.01 (-2.00%)

16:35
10/20/17
10/20
16:35
10/20/17
16:35
Hot Stocks
Breaking Hot Stocks news story on Connecture »

Connecture trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$23.83

0.25 (1.06%)

, PG

Procter & Gamble

$88.25

-3.34 (-3.65%)

16:31
10/20/17
10/20
16:31
10/20/17
16:31
General news
On The Fly: Top stock stories for Friday »

Stocks opened sharply…

GE

General Electric

$23.83

0.25 (1.06%)

PG

Procter & Gamble

$88.25

-3.34 (-3.65%)

CELG

Celgene

$121.33

-14.63 (-10.76%)

SNCR

Synchronoss

$11.39

-0.12 (-1.04%)

IL

Bought by SNCR

SKX

Skechers

$33.99

9.96 (41.45%)

PYPL

PayPal

$70.97

3.72 (5.53%)

NCR

NCR Corp.

$33.05

-4 (-10.80%)

LHO

LaSalle Hotel

$28.52

-1.94 (-6.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 08

    Nov

  • 08

    Nov

  • 29

    Nov

  • 30

    Nov

16:30
10/20/17
10/20
16:30
10/20/17
16:30
Options
Preliminary option volume of 22.9M today »

Preliminary option volume…

MKL

Markel

$1,078.23

14.88 (1.40%)

, SNC

State National

$21.05

0.02 (0.10%)

16:26
10/20/17
10/20
16:26
10/20/17
16:26
Conference/Events
State National to host special shareholder meeting »

Special Shareholder…

MKL

Markel

$1,078.23

14.88 (1.40%)

SNC

State National

$21.05

0.02 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 26

    Oct

RYTM

Rhythm Pharmaceuticals

$23.08

-0.17 (-0.73%)

16:22
10/20/17
10/20
16:22
10/20/17
16:22
Hot Stocks
Breaking Hot Stocks news story on Rhythm Pharmaceuticals »

Orbimed Advisors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.